Aducanumab Lowers Amyloid Plaque Associated with Alzheimer’s, Extension Trial Shows

Aducanumab Lowers Amyloid Plaque Associated with Alzheimer’s, Extension Trial Shows
Aducanumab reduced deposits of the amyloid plaque associated with Alzheimer's disease in the brains of early-stage patients who took part in a three-year extension trial, Biogen reports. After the study ended, deposits of the protein were lower in many patients' brains than the level that a scan would identify as constituting Alzheimer's, researchers said. The treatment is now in Phase 3 clinical treats. Imaging showed that a fourth of the 143 patients in the extension study experienced brain swelling from the treatment. But most did not experience symptoms from it, and it was temporary in the majority of cases. Researchers in the Phase 1 trial (NCT01677572) randomly assigned patie
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *